A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Adult
Age Factors
Aged
Alveolitis, Extrinsic Allergic
/ diagnosis
Canada
/ epidemiology
Cluster Analysis
Comorbidity
Disease Progression
Female
Humans
Idiopathic Pulmonary Fibrosis
/ diagnosis
Lung Diseases, Interstitial
/ diagnosis
Male
Middle Aged
Prospective Studies
Risk Assessment
Risk Factors
Sex Factors
Sleep Apnea, Obstructive
/ epidemiology
Smoking
/ adverse effects
Time Factors
Comorbidities
Interstitial lung disease
Outcomes
Pulmonary fibrosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
07 Dec 2020
07 Dec 2020
Historique:
received:
16
09
2020
accepted:
19
11
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
8
10
2021
Statut:
epublish
Résumé
Comorbidities are frequent and have been associated with poor quality of life, increased hospitalizations, and mortality in patients with interstitial lung disease (ILD). However, it is unclear how comorbidities lead to these negative outcomes and whether they could influence ILD disease progression. The goal of this study was to identify clusters of patients based on similar comorbidity profiles and to determine whether these clusters were associated with rate of lung function decline and/or mortality. Patients with a major fibrotic ILD (idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, connective tissue disease-associated ILD, and unclassifiable ILD) from the CAnadian REgistry for Pulmonary Fibrosis (CARE-PF) were included. Hierarchical agglomerative clustering of comorbidities, age, sex, and smoking pack-years was conducted for each ILD subtype to identify combinations of these features that frequently occurred together in patients. The association between clusters and change in lung function over time was determined using linear mixed effects modeling, with adjustment for age, sex, and smoking pack-years. Kaplan Meier curves were used to assess differences in survival between the clusters. Discrete clusters were identified within each fibrotic ILD. In IPF, males with obstructive sleep apnea (OSA) had more rapid decline in FVC %-predicted (- 11.9% per year [95% CI - 15.3, - 8.5]) compared to females without any comorbidities (- 8.1% per year [95% CI - 13.6, - 2.7]; p = 0.03). Females without comorbidities also had significantly longer survival compared to all other IPF clusters. There were no significant differences in rate of lung function decline or survival between clusters in the other fibrotic ILD subtypes. The combination of male sex and OSA may portend worse outcomes in IPF. Further research is required to elucidate the interplay between sex and comorbidities in ILD, as well as the role of OSA in ILD disease progression.
Sections du résumé
BACKGROUND
BACKGROUND
Comorbidities are frequent and have been associated with poor quality of life, increased hospitalizations, and mortality in patients with interstitial lung disease (ILD). However, it is unclear how comorbidities lead to these negative outcomes and whether they could influence ILD disease progression. The goal of this study was to identify clusters of patients based on similar comorbidity profiles and to determine whether these clusters were associated with rate of lung function decline and/or mortality.
METHODS
METHODS
Patients with a major fibrotic ILD (idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, connective tissue disease-associated ILD, and unclassifiable ILD) from the CAnadian REgistry for Pulmonary Fibrosis (CARE-PF) were included. Hierarchical agglomerative clustering of comorbidities, age, sex, and smoking pack-years was conducted for each ILD subtype to identify combinations of these features that frequently occurred together in patients. The association between clusters and change in lung function over time was determined using linear mixed effects modeling, with adjustment for age, sex, and smoking pack-years. Kaplan Meier curves were used to assess differences in survival between the clusters.
RESULTS
RESULTS
Discrete clusters were identified within each fibrotic ILD. In IPF, males with obstructive sleep apnea (OSA) had more rapid decline in FVC %-predicted (- 11.9% per year [95% CI - 15.3, - 8.5]) compared to females without any comorbidities (- 8.1% per year [95% CI - 13.6, - 2.7]; p = 0.03). Females without comorbidities also had significantly longer survival compared to all other IPF clusters. There were no significant differences in rate of lung function decline or survival between clusters in the other fibrotic ILD subtypes.
CONCLUSIONS
CONCLUSIONS
The combination of male sex and OSA may portend worse outcomes in IPF. Further research is required to elucidate the interplay between sex and comorbidities in ILD, as well as the role of OSA in ILD disease progression.
Identifiants
pubmed: 33287805
doi: 10.1186/s12931-020-01579-7
pii: 10.1186/s12931-020-01579-7
pmc: PMC7720501
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
322Références
ERJ Open Res. 2019 Dec 08;5(4):
pubmed: 31832430
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751416
Lancet Respir Med. 2016 Dec;4(12):969-979
pubmed: 27864036
Can Respir J. 2016;2016:3562923
pubmed: 27445528
Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):357-62
pubmed: 10934053
Chest. 2007 May;131(5):1448-53
pubmed: 17400656
Respir Res. 2018 Apr 25;19(1):73
pubmed: 29695236
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Respirology. 2019 Oct;24(10):996-1004
pubmed: 30933419
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):103-10
pubmed: 21319592
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
pubmed: 11790668
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Eur Respir J. 2018 Sep 16;52(3):
pubmed: 30072505
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMC Pulm Med. 2019 Nov 27;19(1):223
pubmed: 31771541
Respir Res. 2018 May 25;19(1):101
pubmed: 29801506
PLoS One. 2016 Mar 29;11(3):e0151425
pubmed: 27023440
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761
pubmed: 28471697